Topotecan Episcleral Plaque for Treatment of Retinoblastoma

Summary

This single-arm, non-randomized, dose escalation phase I clinical trial will assess primarily the safety and secondarily the efficacy of episcleral topotecan in patients with active de novo or recurrent intraocular retinoblastoma in at least one eye following completion of first-line therapy.

Timeline

Start

2021-06-16

Primary completion

2024-10-01

Completion

2024-10-14

Drugs

Indications